| abstract |
The present invention relates to a protein tyrosine kinase modulator, particularly 6- {difluoro [6- (1-methyl-1H-pyrazol-4-yl) [1,2,4] triazolo [4, which is an inhibitor of c-Met. Provided is a method for producing a small amount of 3-b] pyridazin-3-yl] methyl} quinoline by-products. 6- {Difluoro [6- (1-methyl-1H-pyrazol-4-yl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] methyl} quinoline (following) New polymorphs and hydrate forms of formula (I)) and salts, processes for their preparation. A pharmaceutical composition comprising at least one of the polymorphic or hydrated forms or salts. And therapeutic and / or prophylactic use of the composition to cancer. [Selection figure] None |